11/20/2025
🔬 Advancing the Future of Aneurysm Treatment
Proud to announce the FDA has granted Investigational Device Exemption (IDE) approval to launch INSYTE, the first-ever pivotal trial studying intravascular neuro Optical Coherence Tomography (nOCT) for brain aneurysm treatment.
As Co-Principal Investigator, alongside my colleague Dr. Ricardo Hanel, I’m excited to help lead this landmark study with Spryte Medical.
For decades, we’ve relied on imaging modalities that only hint at what’s happening inside intracranial vessels. nOCT changes that — offering micron-level views of vessel walls, devices, and healing, from inside the artery. This could fundamentally reshape how we assess aneurysms and optimize device deployment.
This milestone also reflects the FDA’s commitment to innovation through the TAP program, accelerating access to technologies that can meaningfully improve patient outcomes.
Enrollment begins in early 2026. Grateful for the chance to help bring this next chapter of neurovascular imaging to life. 🧠✨